Diagnostics and Therapeutic Insights in a Severe Case of Mevalonate Kinase Deficiency

Mevalonate kinase deficiency is a rare inborn disorder of isoprenoid and sterol biosynthesis characterized by a recurrent autoinflammatory syndrome and, in most severe cases, psychomotor delay. Clinical manifestations can be very complex and, in some cases, mimic a chronic inflammatory disease. Diagnosis is also complex and often requires immunologic, genetic, and biochemical investigations. There is no standardized therapy, but biological agents could help to control inflammatory complaints in some cases. A severe case of mevalonate kinase deficiency that was associated with nephritis and successfully treated with anakinra (interleukin 1 receptor antagonist) is reported here, and new insights into diagnosis and therapy of this complex disorder are discussed.

[1]  O. Witt,et al.  Neonatal‐onset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS1 gene and response to interleukin‐1 receptor antagonist treatment , 2006, American journal of medical genetics. Part A.

[2]  P. Emery,et al.  Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism , 2006, Annals of the rheumatic diseases.

[3]  T. Matsubayashi,et al.  Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. , 2006, Acta paediatrica.

[4]  A. Ventura,et al.  Diagnostic challenge of hyper-IgD syndrome in four children with inflammatory gastrointestinal complaints , 2006, Scandinavian journal of gastroenterology.

[5]  H. Simon,et al.  Therapeutic interleukin (IL) 1 blockade normalises increased IL1β and decreased tumour necrosis factor α and IL10 production in blood mononuclear cells of a patient with CINCA syndrome , 2005, Annals of the rheumatic diseases.

[6]  J. Meer,et al.  Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. , 2005, The Netherlands journal of medicine.

[7]  J. Serratrice,et al.  Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. , 2005, Rheumatology.

[8]  R. Ravazzolo,et al.  MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever , 2005, European Journal of Human Genetics.

[9]  K. Gibson,et al.  Mevalonate kinase assay using DEAE-cellulose column chromatography for first-trimester prenatal diagnosis and complementation analysis in mevalonic aciduria , 1992, Journal of Inherited Metabolic Disease.

[10]  K. Gibson,et al.  Mevalonic aciduria: Pathobiochemical effects of mevalonate kinase deficiency on cholesterol metabolism in intact fibroblasts , 1988, Journal of Inherited Metabolic Disease.

[11]  A. Ventura,et al.  Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever. , 2004, Clinical and experimental rheumatology.

[12]  N. Wulffraat,et al.  Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. , 2004, Arthritis and rheumatism.

[13]  J. Meer,et al.  Simvastatin Treatment for Inflammatory Attacks of the Hyperimmunoglobulinemia D and Periodic Fever Syndrome , 2004, Clinical pharmacology and therapeutics.

[14]  P. Hawkins,et al.  Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. , 2004, Arthritis and rheumatism.

[15]  H. Waterham,et al.  Mevalonate kinase deficiency in a child with periodic fever and without hyperimmunoglobulinaemia D , 2001, Journal of Inherited Metabolic Disease.

[16]  H. Waterham,et al.  Mevalonate kinase deficiency: enlarging the clinical and biochemical spectrum. , 2003, Pediatrics.

[17]  Richard Kelley,et al.  Hereditary periodic fever. , 2002, The New England journal of medicine.

[18]  L. Cuisset,et al.  Molecular Analysis of the Mevalonate Kinase Gene in a Cohort of Patients with the Hyper-IgD and Periodic Fever Syndrome: Its Application as a Diagnostic Tool , 2001, Annals of Internal Medicine.

[19]  H. Waterham,et al.  Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. , 2001, Rheumatology.

[20]  J. de Dios García-Díaz,et al.  Glucocorticoids but not NSAID abort attacks in hyper-IgD and periodic fever syndrome. , 2001, The Journal of rheumatology.

[21]  R. Wanders,et al.  Biochemical and genetic aspects of mevalonate kinase and its deficiency. , 2000, Biochimica et biophysica acta.

[22]  H. Waterham,et al.  Mevalonate kinase deficiency and Dutch type periodic fever. , 2000, Clinical and experimental rheumatology.

[23]  Joost P.H. Drenth,et al.  Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome , 1999, Nature Genetics.

[24]  J. V. D. van der Meer,et al.  Hyperimmunoglobulinemia D and Periodic Fever Syndrome: The Clinical Spectrum in a Series of 50 Patients , 1994, Medicine.

[25]  K. Sartor,et al.  Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. , 1993, Pediatrics.

[26]  S. Baudner.  Why a new international reference preparation (IRP) for human plasma proteins? , 1993, Journal of clinical laboratory analysis.

[27]  W. H. Elliott,et al.  Automated screening of urine samples for carbohydrates, organic and amino acids after treatment with urease. , 1991, Journal of chromatography.

[28]  S. Harvey.  Comparison of the gradient elution separations for organic and inorganic anions with chemically suppressed conductometric detection , 1991 .